


Olaparib

Printed from <https://www.cancerquest.org/es/node/6417> on 02/24/2026



Brand name: Lynparza®

IUPAC: 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one

FDA approval: Yes

[Enlace del fabricante](#)

Usage:

Consider the interruption or reduction of the dose to manage adverse reactions. Recommended dose: 200 mg (four capsules of 50 mg) orally twice daily. If a further dose reduction is required, reduce to 100 mg (two capsules of 50 mg) orally twice daily.

Mechanism:

The PARP inhibitors act by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA damage. In certain tumor cells, such as those with the BRCA mutation, blocking this enzyme can lead to cell death. Women with BRCA mutations have a higher risk of developing certain types of cancer, including ovarian and breast cancer.

Side effects:

Common side effects of this medication include nausea, vomiting, fatigue, diarrhea, indigestion, headache, appetite problems, cold-like symptoms, cough, skin rash, and joint pain.